Paul J. Diaz
President and CEO at Myriad Genetics Inc.
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 3 boards, counting each seat separately. Longest: Myriad Genetics Inc., 3 years.
Myriad Genetics Inc.
Director · President and CEO
DaVita Inc.
Director
Centene Corporation
Director
Chief executive roles
Myriad Genetics Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 28, 2026 | Centene Corporation | Grant or award | +2,771 | — | — |
| Mar 24, 2025 | Myriad Genetics Inc. | Shares withheld for tax | −18,312 | $9.98 | $182,754 |
| Mar 24, 2025 | Myriad Genetics Inc. | Shares withheld for tax | −26,827 | $9.98 | $267,733 |
| Mar 22, 2025 | Myriad Genetics Inc. | Shares withheld for tax | −19,859 | $10.01 | $198,789 |
| Mar 22, 2025 | Myriad Genetics Inc. | Shares withheld for tax | −52,682 | $10.01 | $527,347 |
| Mar 15, 2025 | Myriad Genetics Inc. | Shares withheld for tax | −30,118 | $10.07 | $303,288 |
| Mar 14, 2025 | Myriad Genetics Inc. | Shares withheld for tax | −37,564 | $10.07 | $378,269 |
| Feb 7, 2025 | Myriad Genetics Inc. | Grant or award | +114,828 | — | — |
| Oct 11, 2024 | Myriad Genetics Inc. | Open-market sale | −15,000 | $22.93 | $343,950 |
| Sep 11, 2024 | Myriad Genetics Inc. | Open-market sale | −15,000 | $26.72 | $400,800 |
| Aug 13, 2024 | Myriad Genetics Inc. | Shares withheld for tax | −22,808 | $28.18 | $642,729 |
| Aug 13, 2024 | Myriad Genetics Inc. | Shares withheld for tax | −50,980 | $28.18 | $1,436,616 |
| May 15, 2024 | Myriad Genetics Inc. | Open-market sale | −75,000 | $25.07 | $1,880,250 |
| May 14, 2024 | Myriad Genetics Inc. | Open-market sale | −95,000 | $25.21 | $2,394,950 |
| May 13, 2024 | Myriad Genetics Inc. | Open-market sale | −57,844 | $25.13 | $1,453,620 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.